A Phase 2a, Randomized, Double-Blind, Active And Placebo-Controlled Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2016
At a glance
- Drugs Fosdagrocorat (Primary) ; Prednisone
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 29 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 29 Oct 2013 Primary endpoint 'Disease-activity-score' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History